Chart: Iressa Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Iressa Clinical Development
You may also be interested in...
Iressa Clinical Development Timeline
Chronicle of the development and review of AstraZeneca’s tyrosine kinase inhibitor gefitinib for EGFR mutation-positive non-small cell lung cancer.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product